SEC Form 4 · accession 0001468316-26-000017
FENNEC PHARMACEUTICALS INC. · FENC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rosty Raykov
Other
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001211583
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common sharesF1 | Jul 1, 2026 | A | 2,778 | $0.00 | A | 132,857 | D | |
| Common sharesF2 | Jul 1, 2026 | M | 15,597 | $2.45 | A | 148,454 | D | |
| Common sharesF3 | Jul 1, 2026 | S | 9,599 | $10.41 | D | 138,855 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF4 | $2.45 | Jul 1, 2026 | M | 15,597 | D | Jul 5, 2016 | Jul 5, 2026 | options | 15,597 | 1,525,000 | D |
Explanation of responses
- F1Represents shares released from restriction from shares awarded 5/16/2024.
- F2Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025.
- F3Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025.
- F4Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025.